Discovery of TMPRSS2 Inhibitors from Virtual Screening as a Potential Treatment of COVID-19

Xin Hu,* Jonathan H. Shrimp, Hui Guo, Miao Xu, Catherine Z. Chen, Wei Zhu, Alexey V. Zakharov, Sankalp Jain, Paul Shinn, Anton Simeonov, Matthew D. Hall, and Min Shen*

Cite This: ACS Pharmacol. Transl. Sci. 2021, 4, 1124−1135

ABSTRACT: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has prompted researchers to pivot their efforts to finding antiviral compounds and vaccines. In this study, we focused on the human host cell transmembrane protease serine 2 (TMPRSS2), which plays an important role in the viral life cycle by cleaving the spike protein to initiate membrane fusion. TMPRSS2 is an attractive target and has received attention for the development of drugs against SARS and Middle East respiratory syndrome. Starting with comparative structural modeling and a binding model analysis, we developed an efficient pharmacophore-based approach and applied a large-scale in silico database screening for small-molecule inhibitors against TMPRSS2. The hits were evaluated in the TMPRSS2 biochemical assay and the SARS-CoV-2 pseudotyped particle entry assay. A number of novel inhibitors were identified, providing starting points for the further development of drug candidates for the treatment of coronavirus disease 2019.

KEYWORDS: SARS-CoV-2, COVID-19, TMPRSS2, pharmacophore model, virtual screening

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus responsible for the ongoing coronavirus disease 2019 (COVID-19) pandemic.1 It is a novel betacoronavirus from the same family as SARS-CoV and the Middle East respiratory syndrome (MERS).2 SARS-CoV-2 produces clinical symptoms that include fever, dry cough, sore throat, dyspnea, headache, pneumonia with potentially progressive respiratory failure owing to alveolar damage, and even death.3 Recently it has also been reported that COVID-19 is associated with the amplified incidence of thrombotic events, which contribute to severe coagulation in different organs such as the lung, brain, liver, heart, and kidney and further lead to multiorgan failure and death.4,5 SARS-CoV-2 is a global pandemic with millions of documented infections worldwide, and over 1 million deaths reported by the World Health Organization (WHO). Since no antiviral drug or vaccine existed to treat or prevent SARS-CoV-2, potential therapeutic strategies that are currently being evaluated predominantly stem from previous experience with treating SARS-CoV, MERS-CoV, and other emerging viruses.6−8 Most nations are primarily making efforts to prevent the further spread of this potentially deadly virus by implementing preventive and control strategies.

A number of processes are considered essential to the viral lifecycle and therefore provide a significant number of targets for inhibiting viral replication. The screening of anti-COVID-19 drugs by using clinical and approved compounds can greatly shorten the research and development cycle. Some screening campaigns of approved drug libraries and pharmacologically active molecules have been conducted for the discovery of SARS-CoV-2 inhibitors. Antiparasitic drugs like chloroquine and its derivative hydroxychloroquine have shown antiviral activity against SARS-CoV-2 in an in vitro cytopathic assay and had an Emergency Use Authorization awarded and rescinded by the United States Food & Drug Administration (FDA).9,10 Zn(2+) was found to inhibit coronavirus through blocking the initiation step of equine arteritis virus RNA synthesis in vitro, and zinc ionophores inhibit the replication of coronavirus in cell culture.11−13 Besides having direct antiviral effects, chloroquine and hydroxychloroquine specifically target extracellular zinc to intracellular lysosomes, where it interferes with the RNA-dependent RNA polymerase activity and inhibits a coronavirus replication.14 The broad-spectrum antibacterial macrolide azithromycin, an inhibitor of bacterial protein synthesis, also has significant antiviral properties, and it
decreased the coronavirus infection in a cell culture.\textsuperscript{13} The antiviral lopinavir, a protease inhibitor, has also shown an inhibitory activity of SARS-CoV-2 infection in Vero E6 cells.\textsuperscript{14} The experimental drug remdesivir, a nucleoside analogue, originally developed against other viruses, has been approved by the FDA as treatment for COVID-19.\textsuperscript{9,15} Despite numerous biochemical- and cell-based drug repurposing screenings of drug compound libraries that have identified a number of potent antivirals targeting various stages of the viral life cycle, the development of effective intervention strategies relies on the knowledge of molecular and cellular mechanisms of coronavirus infections, which highlights the significance of studying virus-host interactions at the molecular level to identify targets for antiviral intervention and to elucidate critical viral and host determinants that are decisive for the development of severe disease.\textsuperscript{16}

The cell entry of coronaviruses depends on the binding of the viral spike (S) proteins to human cellular receptors and on the S protein priming by host cell proteases. It has been demonstrated that SARS-CoV-2 uses the human host cell angiotensin-converting enzyme 2 (ACE2) as the entry receptor and the transmembrane protease serine 2 (TMPRSS2) for the S protein priming.\textsuperscript{17,18} TMPRSS2 has an extracellular protease domain capable of cleaving a spike protein domain to initiate membrane fusion. Considering the vital role played by TMPRSS2 in the viral life cycle, this protease has received great attention for use as a potential target to inhibit a viral entry into host cells.\textsuperscript{19–21} Bestle et al. used an antiseismic peptide conjugate to interfere with splicing resulting in the expression of a truncated, enzymatically dead TMPRSS2. This is the most targeted experiment showing that the dissociation constant $K_d$ of enzymatic activity lowered the cytopathic effect, viral spread, and replication of SARS-CoV-2 in Calu-3 cells.\textsuperscript{22} More recently, Hoffmann et al. showed that camostat mesylate and its metabolite can lower the viral entry in Calu-3 cells, where there is a TMPRSS2-dependent viral entry. Additionally, they showed from single-cell RNA-Seq data sets that 53% of ACE2 expressing cells coexpress TMPRSS2 in lungs, indicating that the tissue-specific TMPRSS2 is the dominant activating protease in lung.\textsuperscript{23}

Previous basic and clinical research on coronaviruses has led to the identification of many potential drug targets and the determination of their X-ray crystal structures. Structure-based drug design by virtual screening and molecular docking studies has become a valuable primary step in the identification of novel lead molecules for the potential treatment of COVID-19.\textsuperscript{24} In this study, we performed a comprehensive structural modeling and binding-site analysis of the serine protease TMPRSS2, followed by a structure-based virtual screening against the National Center for Advancing Translational Sciences (NCATS) library consisting of up to 200 000 drug-like compounds designed from a diverse chemical space. After an extensive postdocking analysis in combination with a clustering analysis and visual inspection, 350 compounds were selected for an experimental validation based on their binding free energy, consensus docking score, and binding interactions with key residues surrounding the active site. The selected hits were evaluated in the TMPRSS2 biochemical assay and the SARS-CoV-2-S pseudotyped particle (PP) entry assay.\textsuperscript{25,26} A number of novel inhibitors were identified, providing a starting point for the further development of therapeutic drug candidates for COVID-19.

### MATERIALS AND METHODS

#### Homology Modeling of TMPRSS2

An amino acid sequence of human TMPRSS2 was obtained from the UniProtKB (Access No. O15393). The protein consisting of 492 amino acid residues is a zymogen cleaved at Arg-255. The protease domain (255–492) is located at the C terminus of the extracellular region, which also contains a scavenger receptor cysteine-rich (SRCR) activation domain (150–242) and a short low-density lipoprotein receptor class A (LDLRA) domain (113–148). We modeled the three-dimensional (3D) structure of TMPRSS2 SRCR and peptidase S1 domain (150–492) using the threading program I-TASSER.\textsuperscript{27} The transmembrane trypsin-like serine protease hepsin (also known as TMPRSS1, gene HPN), which shares 35% of its sequence identity with TMPRSS2, was used as the template structure (Protein Data Bank (PDB) code 1Z8G).\textsuperscript{28} An overlay of the TMPRSS2 structure model with the template hepsin and another two related serine proteases, namely, coagulation factor Xa (PDB 1KSN)\textsuperscript{29} and urokinase (PDB 1F92),\textsuperscript{30} is shown in Figure S1. The generated structure was validated using the tools (PROCHECK, ERRAT, Verify3D, PROVE, and WHATCHECK) in the SAVES server (https://saves.mbi.ucla.edu/). The modeled structure passed in all programs, indicating a good quality overall. Finally, the 3D structure of TMPRSS2 was refined by a thorough energy minimization and molecular dynamics (MD) simulations as described below.

#### Molecular Docking and MD Simulations

Three TMPRSS2 inhibitors—nafamostat, camostat, and gabexate—were used in this study. Nafamostat mesylate is an approved anticoagulant in Asian countries and is currently in Phase 3 clinical trials for COVID-19.\textsuperscript{31} Camostat mesylate was approved for human use in Japan for the treatment of chronic pancreatitis and postoperative reflux esophagitis. It is a broad-spectrum serine protease inhibitor targeting coronavirus and filovirus entry.\textsuperscript{32} Gabexate is an investigational drug and serine protease inhibitor used to prevent blood clots and reduce the production of inflammatory cytokines.\textsuperscript{33} The activities of these inhibitors against TMPRSS2 have been confirmed in our recent report, with half-maximal inhibitory concentration ($IC_{50}$) values of 0.27, 6.2, and 130 nM, respectively.\textsuperscript{25}

Consensus docking studies of these small-molecule inhibitors to the modeled structure of TMPRSS2 were performed using MOE Dock in the Molecular Operating Environment program\textsuperscript{34} and AutoDock Vina.\textsuperscript{35} Prior to docking, the 3D structure of TMPRSS2 was prepared using the Structure Preparation module in MOE. The ligand-induced fit docking protocol in MOE Dock was applied, and the binding affinity was evaluated using the GBVI/WSA score. The default parameters in AutoDock Vina were used with a grid box centered on the O atom of the side chain of the catalytic residue Ser441. The size of the grid box was defined by 20 × 20 × 20 Å to encompass the entire active site of the protein. The top-ranked 10 poses from MOE Dock and AutoDock Vina were retained and visually inspected. The consensus binding models with lowest binding energies were selected for further MD simulations.

MD simulations of the TMPRSS2 in the apo form and inhibitor-bound complexes were conducted using the AMBER18 package.\textsuperscript{36} The protein was protonated at pH 7. The catalytic residue His296 was protonated as the N-δ form so that it formed H-bonding with Ser441 and Asp345. The solvated protein systems were subjected to a thorough energy
minimization prior to MD simulations by first minimizing the water molecules while holding the solute frozen (1000 steps using the steepest descent algorithm), followed by 5000 steps of conjugate gradient minimization of the whole system to relax the system. Periodic boundary conditions were applied to simulate a continuous system. The particle mesh Ewald (PME) method was employed to calculate the long-range electrostatic interactions. The simulated system in an explicit solvate was first subjected to a gradual temperature increase from 0 to 300 K over 100 ps and then equilibrated for 500 ps at 300 K, followed by a production run of 100 ns. Trajectory analysis and MM-GBSA binding free energy calculations were performed using the cpptraj and MMPB/GBSA module in the AmberTools

Pharmacophore-Based Virtual Screening. A stepwise virtual screening (VS) protocol combining ligand- and structure-based approaches was employed to screen the NCATS’s in-house screening libraries consisting of nearly 200,000 drug-like compounds. Pharmacophore models were generated based on the predicted binding interactions of TMPRSS2 with inhibitors camostat, nafamostat, and gabexate using MOE. Four pharmacophoric features were included: (1) a Don2-projected H-bond donor feature placed on the side chain of Asp435 in the S1 pocket; (2) an Acc2-projected H-bond acceptor feature placed on the N atom of the side chain of Asp435 in the S1 pocket; (3) a hydrophobic centroid Hyd feature matching hydrophobic interactions at the S1’ hydrophobic region mainly formed by Val275, Val280, and Leu302; (4) a Don2-projected H-bond donor feature placed on the side chain of Glu299. The first two pharmacophores were selected based on (1) a structural representative of each cluster, (2) the predicted binding energy, (3) the H-bond interaction with key residues at each binding site, and (4) promiscuous compounds with potential undesirable functionalities and PAINS alert were generally discarded.

TMPRSS2 Biochemical Assay. A TMPRSS2 biochemical assay has been developed to evaluate the activity of compounds against TMPRSS2. The assay was performed according to the assay protocol: to a 1536-well black plate was added a Boc-Gln-Ala-Arg-AMC substrate (20 nL) and test compound (20 nL in dimethyl sulfoxide (DMSO)) using an ECHO 655 acoustic dispenser (LabCyte). To that was dispensed TMPRSS2 diluted in an assay buffer (50 mM Tris pH 8, 150 mM NaCl, 0.01% Tween20) using a BioRAPTR (Beckman Coulter) to give a total assay volume of 5 μL. After 1 h of incubation at room temperature, the fluorescence was measured using the PHERAstar with an excitation at 340 nm and emission at 440 nm.

Fluorescence Counter Assay. This counter assay was performed as described previously. To a 1536-well black plate (Corning catalog 3724) was added 7-amino-4-methylcoumarin (20 nL) and inhibitor or DMSO (20 nL) using an ECHO 655 acoustic dispenser (LabCyte). To that was added an assay buffer (50 mM Tris pH 8, 150 mM NaCl, 0.01% Tween20) to give a total reaction volume of 5 μL. Detection was done using the PHERAstar with excitation: 340 nm and emission: 440 nm. The fluorescence was normalized relative to a negative control 7-amino-4-methylcoumarine. An inhibitor causing fluorescence quenching would be identified as having a concentration-dependent decrease on AMC fluorescence.

SARS-CoV-2-S Pseudotyped Particle Entry Assays. A SARS-CoV-2 Spike pseudotyped particle (PP) entry assay was performed as previously described. In short, 40,000 cells/well Calu3 cells (catalog HTB-55, ATCC) were seeded in white, solid bottom 96-well microplates (Greiner BioOne) in 100 μL/well media and incubated at 37 °C with 5% CO2 overnight (~16 h). Then, the supernatant was removed, and compounds were added as 50 μL/well, 2X solutions in media. Cells were incubated with compounds for 1 h at 37 °C with 5% CO2, before 50 μL/well of SARS-CoV-2-S pseudotyped particles (PP) was added. We used the PP pseudotyped SARS-CoV-2 spike from the South African variant B.1.351 (catalog CB-97100-154, Codex Biosolutions) with a C-terminal 19 amino
acid deletion using the murine leukemia virus system as previously described.\(^{40}\) The plates were then spinoculated by centrifugation at 1500 rpm (453g) for 45 min and incubated for 48 h at 37 °C with 5% CO\(_2\) to allow the cell entry of PP and the expression of the luciferase reporter. After the incubation, the supernatant was removed, and 100 μL/well of the Bright-Glo Luciferase detection reagent (Promega) was added to assay plates and incubated for 5 min at room temperature. The luminescence signal was measured using a PHERAStar plate reader (BMG Labtech). The data were normalized with wells containing SARS-CoV-2-S PPs as 100% and wells containing control bald PP as 0%. A cytotoxicity counter screen was performed using the same protocol without the addition of PP, with an adenosine triphosphate (ATP) content assay kit (CellTiterGlo, Promega).

### RESULTS

**Binding Interaction of TMPRSS2 Inhibitor.** TMPRSS2 shares 35% of its sequence identity with the transmembrane trypsin-like serine protease hepsin. The modeled structure of TMPRSS2 generated from I-TASSER had a C score of ~0.10 and a TM score of 0.70, which indicated a good quality modeled structure.\(^{27}\) Similar to the template hepsin and other trypsin-like proteases, TMPRSS2 shares a common structural fold with conserved triad residues Ser441, His296, and Asp345 at the active site for catalytic activity.\(^{41,42}\) A predicted oxyanion hole is formed by conserved residues Gly439 and Gln438 at the active site for the catalytic process and a highly hydrophobic S1 pocket with a conserved Asp345, which is essential for substrate and inhibitor binding.

The predicted binding models of camostat, nafamostat, and gabexate to the active site of TMPRSS2 are shown in Figure 1. The three small-molecule inhibitors adopted a similar binding mode at the active site of TMPRSS2. While the ester group of the guanidinobenzonate moiety of camostat and nafamostat binds at the triad catalytic site interacting with Ser441 and Gln438, the guanidinium head points into the S1 pocket. The gabexate binding complex was more dynamical in the apo state (Figure 2A). The loops surrounding the active site exhibited greater dynamics in the apo form but were generally stabilized in the inhibitor binding complex over the time course of 100 ns simulations. The hydrogen bonds between the guanidinium head and residue Asp435 in the S1 pocket remained stable in the inhibitor binding complexes (Figures S2 and S3). The gabexate binding complex was more dynamical in the MD simulations, which may explain its weaker activity as compared to camostat and nafamostat. Notably, residues Glu299 and Gln438 were found to be rather flexible in the MD simulations. These residues are in the active site adjacent to the catalytic triad, which likely plays an important role in facilitating the substrate recognition as well as inhibitor binding.

**Pharmacophore-Based Virtual Screening.** On the basis of the binding model analysis we developed a pharmacophore model and applied it in a virtual screening for novel inhibitors of TMPRSS2. Four pharmacophores were derived from the predicted binding interactions of the three known inhibitors (Figure S4). Two binding elements were selected as essential features: the first is a H-bonding interaction between Asp435 and a functional head in the S1 pocket; the second is a core H-bonding interaction with Gln438, which facilitates inhibitor...
binding with the triad residues at the catalytic site. The other two pharmacophoric features included the hydrophobic interactions at the S1′ pocket mainly formed by Val275, Val280, and Leu302, which serves as an extended region to accommodate variable groups for an enhanced binding affinity; the other one is a binding interaction with Glu299, which provides a key to position the inhibitor into the binding pocket.

Virtual screening was performed in a stepwise way combined with pharmacophore-based searching, 3D-shape-based mapping, and structure-based docking (Figure 3). An in-house collection of nearly 200,000 drug-like compounds was virtually screened. The pharmacophore model was first applied, and compounds matching at least two pharmacophores were extracted. To enrich the structural diversity of potential hits, the 3D shape-based searching was applied using the predicted binding conformations of three inhibitors as a query. A total of 20,000 compounds was assembled from the pharmacophore- and ligand-based searches, followed by a structure-based docking to the active site of TMPRSS2 for a binding interaction evaluation. To prioritize the hits generated from docking, several postprocessing approaches were applied including docking pose analysis, structural clustering, rescoring, and promiscuity filtering. Ultimately, ~350 compounds were selected based on the predicted binding energy, key interactions within the catalytic triad and functional head in the S1 pocket, and the novelty of scaffold and chemotypes. Promiscuous compounds (i.e., those shown to have high hit rates across high-throughput screening (HTS) assays experimentally screened at NCATS) with potential undesirable functionalities and PAINS alerts were generally discarded.

**TMPRSS2 Inhibitors Identified from VS.** All selected compounds were evaluated in the TMPRSS2 enzymatic assay, a fluorogenic biochemical assay we reported recently. A counter assay was conducted to detect all positive compounds with fluorescence quenching properties that suppress the fluorescence signal generated by the protease activity on the fluorogenic substrate. Of 350 compounds tested, 27 hits showed activity against TMPRSS2 with an efficacy greater than 30% and an IC₅₀ value ranging from 1 to 30 μM. The active compounds were further retested in the biochemical and counter assay at 11 concentrations in replicate (Table 1 and Figure S5). Figure 4 showed the top hits with an efficacy greater than 50% and an IC₅₀ lower than 10 μM. The three inhibitors camostat, nafamostat, and gabexate were used as positive controls and all showed the same inhibitory activities as previously reported. The best VS hits of NCGC00378763 (otamixaban) and NCGC00421880 showed an IC₅₀ of 0.62 and 0.88 μM. A selective inhibitor of urokinase, UKI-1 (NCGC00522442), showed an IC₅₀ of 2.20 μM with 100% inhibition. While most of these identified inhibitors possess a benzoamidinium headgroup, they are structurally diverse with distinct scaffolds and molecular properties different from those of nafamostat and camostat.

We further tested the inhibitors in an SARS-CoV-2 spike PP entry assay in Calu-3 cells to evaluate their inhibitory activities on viral entry. While the SARS-CoV-2 spike could utilize multiple cellular proteases for entry, entry into the Calu-3 cell has been shown to be predominantly through the TMPRSS2-mediated pathway. The PPs pseudotype the South African variant (B.1.351) spike protein bears the mutations L18F, D80A, D215G, del242-244, K417N, E484K, N501Y, D614G, and A701V. These mutations do not affect the S2′ cleavage site recognized by TMPRSS2. A cytotoxicity counter assay was conducted using the same protocol without the addition of PP. Nafamostat and camostat showed a high potency and efficacy in the SARS-CoV-2 PP assay; however, gabexate did not exhibit an activity on viral entry inhibition (Figure 5). Of the 10 VS inhibitors tested, only otamixaban and NCGC00386945 displayed activity with ~50% efficacy in the PP entry assay.
whereas NCGC00421880 and NCGC00387094 showed SARS-CoV-2 inhibition as well as cytotoxicity in the counter assay (Table 1). No inhibition activity was observed with other inhibitors in the cell-based assay, most likely because of their

Table 1. Activity of TMPRSS2 Inhibitors in the Enzyme Assay and the SARS-COV-2 PP Entry Assay

| Compounds           | Structure | TMPRSS2 | SARS-2 PP | Calu3 cytotoxicity | MM-GBSA (kcal/mol) |
|---------------------|-----------|---------|-----------|-------------------|--------------------|
| NCGC00160398        | [Image]   | N/A     | 0.0005    | 100               | 0.02               | 100                 | 15.85               | 38.74               | -63.56              |
| (Nafamostat)        |           |         |           |                   |                    |                     |                     |                     |                    |
| NCGC00167526        | [Image]   | N/A     | 0.0039    | 100               | 0.09               | 100                 | N/A                 | 0                   | -59.08              |
| (Carboxat)          |           |         |           |                   |                    |                     |                     |                     |                    |
| NCGC00025297        | [Image]   | N/A     | 0.13      | 98.6              | N/A                | 0                   | N/A                 | 0                   | -54.80              |
| (Gabexate)          |           |         |           |                   |                    |                     |                     |                     |                    |
| NCGC00421880        | [Image]   | N/A     | 0.88      | 100               | >30                | 100                 | >30                 | 93.2                | -61.96              |
|                     |           |         |           |                   |                    |                     |                     |                     |                    |
| NCGC00378763        | [Image]   | N/A     | 0.62      | 100               | 15.84              | 50                  | N/A                 | 0                   | -61.49              |
| (Otamixaban)        |           |         |           |                   |                    |                     |                     |                     |                    |
| NCGC00522442        | [Image]   | N/A     | 2.20      | 100               | N/A                | 0                   | N/A                 | 0                   | -48.64              |
| (UKI-1)             |           |         |           |                   |                    |                     |                     |                     |                    |
| NCGC00386945        | [Image]   | N/A     | 1.24      | 82.3              | 0.35               | 50                  | N/A                 | 0                   | -59.09              |
|                     |           |         |           |                   |                    |                     |                     |                     |                    |
| NCGC00485967        | [Image]   | N/A     | 1.40      | 70.6              | N/A                | 0                   | N/A                 | 0                   | -56.89              |
|                     |           |         |           |                   |                    |                     |                     |                     |                    |
| NCGC00591804        | [Image]   | N/A     | 1.39      | 60.0              | N/A                | 0                   | N/A                 | 0                   | -55.24              |
|                     |           |         |           |                   |                    |                     |                     |                     |                    |
| NCGC00241049        | [Image]   | N/A     | 7.81      | 100               | N/A                | 0                   | N/A                 | 0                   | -48.78              |
|                     |           |         |           |                   |                    |                     |                     |                     |                    |
| NCGC00387094        | [Image]   | N/A     | 6.21      | 100               | >30                | 100                 | >30                 | 37.1                | -42.72              |
|                     |           |         |           |                   |                    |                     |                     |                     |                    |
| NCGC00487181        | [Image]   | N/A     | 3.50      | 70.0              | N/A                | 0                   | N/A                 | 0                   | -36.11              |
|                     |           |         |           |                   |                    |                     |                     |                     |                    |
| NCGC00634982        | [Image]   | N/A     | 4.93      | 55.6              | N/A                | 0                   | 2.24                | 62.7                | -33.90              |

*The MM-GBSA binding free energy was estimated based on the predicted binding model from docking.*
weak activities against TMPRSS2. We also evaluated three TMPRSS2 inhibitors of avoralstat, PCI-27483, and antipain, which have been reported recently.\textsuperscript{44} While avoralstat displayed a comparable inhibition activity to camostat, the other two protease inhibitors showed $\sim60\%$ efficacy activity in our PP entry assay (Figure S6).

**Binding Interaction of Identified Inhibitors at the Active Site of TMPRSS2.** Finally, we performed docking studies and MD simulations to probe the binding interaction of these identified inhibitors with TMPRSS2. Figure 6 showed the predicted binding model of the top four inhibitors bound at the active site of TMPRSS2. As expected, these small molecules utilized the benzoamidinium headgroup to engage key H-bonding interactions with Asp435 in the S1 pocket, while the tail group was mainly positioned at the S1’ hydrophobic pocket. Other inhibitors showed similar binding
interactions to camostat and nafamostat at the catalytic site and S1’ pocket (Figure S7). MD simulations showed that these inhibitors remained stable at the active site of TMPRSS2. However, unlike camostat and nafamostat binding, which form stable H-bonding interactions between the guanidinobenzoyl moiety and the catalytic triad residues for a covalent acyl-enzyme complex formation, these noncovalent inhibitors do not have such a functionality that makes favorable H-bond interactions at the catalytic site. These inhibitors bound at the active site predominately through a hydrophobic interaction at the S1’ and S2 pocket. The calculated binding free energies based on the predicted binding model of these noncovalent inhibitors were generally consistent with the experimental data (Table 1). Notably, docking analysis showed that otamixaban adopted another distinct binding mode with the pyridine-oxide group pointing to the S2 and S4 binding pocket. The calculated binding free energies of the two binding conformations with TMPRSS2 were −61.49 and −67.69 kcal/mol, suggesting that the second binding mode is likely more favorable (Figure S7). Such a binding mode of otamixaban was also observed in the structure with the coagulation factor Xa. In addition, the bulky trisopropyl-phenylsulfonyl group of UKI-1 was also occupied at the S2 pocket by mainly interacting with Trp461. TMPRSS2 possesses several polar residues including a unique Lys342 at this site, which makes it possible to further optimize the

Figure 6. Predicted binding model of inhibitors (A) otamixaban, (B) NCGC00386945, (C) NCGC00421880, and (D) UKI-1. (E) An overlay of four inhibitors bound at the active site of TMPRSS2 is shown. Protein surface is rendered in a hydrophobic representation.
binding interactions to improve the potency and selectivity to TMPRSS2.

**DISCUSSION**

The host serine protease TMPRSS2 is an attractive target for drug development against SARS-CoV-2. However, unlike viral proteases such as 3Clpro, which has been extensively investigated recently, and despite a large number of inhibitors having been reported, TMPRSS2 has been less studied, and very few compounds have been evaluated in drug repurposing screenings. The enzyme is membrane-associated, making it more challenging to express recombinant protein and study in vitro. Although camostat and nafamostat have progressed into clinical trials for the treatment of COVID-19, these inhibitors also show potent activity against many other trypsin-like serine proteases such as the plasma trypsin-like proteases plasmin and FXIa. Therefore, there is an unmet need for novel and selective candidates of TMPRSS2 inhibition for further drug development. Additionally, in theory the TMPRSS2 inhibitors have potential applications for emerging variants of SARS-CoV-2 along with potential future viral outbreaks beyond SARS-CoV-2.

We began the virtual screening campaign by iteratively searching and docking nearly 200,000 compounds to the active site of TMPRSS2, followed by testing 350 compounds in the enzyme assay. The active compounds were further tested in a cell-based PP assay to evaluate their activities on spike-mediated entry inhibition. Several interesting inhibitors were identified from the structure-based VS. Otamixaban is an experimental anticoagulant direct factor Xa inhibitor that was investigated for the treatment of acute coronary syndrome, but its development was terminated in a Phase III clinical trial due to poor performance. Otamixaban exhibited potent activity with an IC₅₀ of 0.62 μM against TMPRSS2 and an efficient activity in the viral entry assay, indicating that it is a promising candidate for further optimization and drug repurposing. NCGC00386945 is a novel inhibitor that was originally developed as a selective S-HT1D antagonist. It showed activity against TMPRSS2 with an IC₅₀ of 1.24 μM, as well as 50% efficacious activity on the viral entry inhibition. Similar to otamixaban, this novel chemotype of TMPRSS2 inhibitor with drug-like properties is structurally appealing for further lead optimization (Table S1). As shown in the predicted binding model, the substitution of the methyl group at the benzoamidinium headgroup with a polar group may engage a H-bonding interaction with Gln438, thus significantly improving the binding affinity and selectivity to TMPRSS2. UKI-1 is a selective inhibitor of trypsin and uPA. While it displayed a value of IC₅₀ within a single-digit micromolar concentration against TMPRSS2, it did not show activity in our PP entry assay. This was also observed with the inhibitor gabexate, which had an IC₅₀ below a micromolar concentration in the TMPRSS enzyme assay but was inactive in the viral entry cell-based assay. In addition, as revealed from the predicted binding model, further exploration of the binding interactions of this series of UKI-1 inhibitor bound at the S2 hydrophobic pocket would improve the potency and selectivity.

A number of hits identified from the VS that were not reported as serine protease inhibitors also showed inhibition in the TMPRSS2 assay with 50%–70% maximal efficacy. Although these compounds did not show a viral entry inhibition in the PP assay, most likely due to their weak potency and efficacy, they represent a diversity of scaffolds that may serve as starting points for further structure-based optimizations for potent and selective inhibitors against TMPRSS2. Most of these inhibitors possess a benzoamidinium headgroup, reiterating a key role of the functional headgroup for effective binding and inhibition. Indeed, a number of nonamidinium-based compounds that fit well in the active site of TMPRSS2 were selected from VS and tested in the enzyme assay, but none of them showed efficient activity, indicating a challenging problem to design novel inhibitors against this serine protease. NCGC00487181 with a sulfonamide group is an interesting inhibitor. It is a structural analogue of Celecoxib, a COX-2 inhibitor as a nonsteroidal anti-inflammatory drug, which was used for the treatment of COVID-19 and was reported to weakly inhibit the main protease (Mpro) of the virus. NCGC00487181 showed a potency of 3.49 μM of IC₅₀ and 70% of efficacy on TMPRSS2 in the enzyme assay. However, it had significant fluorescent interference in the assay and was inactive in the PP assay; therefore, the mechanism of this interesting series of compounds on SARS-COV-2 viral inhibition needs further investigation through an orthogonal assay platform. In addition, we also identified several quinol-like compounds with ~40% maximal efficacy in the TMPRSS2 enzyme assay (Figure S8). Although these compounds are not structurally interesting as drug candidates and their antiviral activity on SARS-COV-2 needs further validation, they are predominately occupied at the catalytic site of TMPRSS2 by catching H-bonding interactions with the triad residue and, therefore, may provide a template for a hybrid design of novel inhibitors against TMPRSS2.

It is worth mentioning that the inhibitors identified from this VS campaign are expected to be noncovalent protease inhibitors. On the one hand, this is in part due to the mechanism of a docking-based approach, which is not capable of identifying a covalent binder. On the other hand, we were inclined to deprioritize the traditional covalent protease inhibitors in the VS in order to identify novel and noncovalent chemotypes. Compared to the covalent inhibitors such as camostat and nafamostat with a reactive functional group to the highly conserved catalytic site, the noncovalent inhibitors are less chemically and metabolically reactive; therefore, these are more advantageous and attractive in the design of selective inhibitors. A number of noncovalent inhibitors of serine proteases thrombin and factor Xa have been reported with better selectivity. As revealed from the binding models of these identified inhibitors, TMPRSS2 showed different structural features and binding specificity at the distal hydrophobic pocket, which makes it a promising target for a structure-based design and chemistry lead optimization to achieve selectivity and drug-like properties as drug candidates for the treatment of COVID-19.

**ASSOCIATED CONTENT**

*Supporting Information*

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acsptsci.0c00221.

Details of the TMPRSS structural model and MD simulations; pharmacophore model of TMPRSS2 used for virtual screening; experimental data of identified TMPRSS2 inhibitors, their predicted binding models, and calculated chemical properties (PDF)
**AUTHOR INFORMATION**

Corresponding Authors
Xin Hu — National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland 20850, United States; orcid.org/0000-0003-1164-5130; Email: hux61@mail.nih.gov

Min Shen — National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland 20850, United States; Email: shenmin@mail.nih.gov

**AUTHORS**

Jonathan H. Shrimp — National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland 20850, United States

Hui Guo — National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland 20850, United States

Miao Xu — National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland 20850, United States

Catherine Z. Chen — National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland 20850, United States

Wei Zhu — National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland 20850, United States

Alexey V. Zakharov — National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland 20850, United States

Sankalp Jain — National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland 20850, United States

Paul Shinn — National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland 20850, United States

Anton Simeonov — National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland 20850, United States

Matthew D. Hall — National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland 20850, United States; orcid.org/0000-0002-5073-442X

Complete contact information is available at: https://pubs.acs.org/10.1021/acsptsci.0c00221

**NOTES**

The authors declare no competing financial interest.

**ACKNOWLEDGMENTS**

This work was supported by the Intramural Research Programs of the National Center for Advancing Translational Sciences, National Institutes of Health.

**REFERENCES**

(1) Lai, C. C., Shih, T. P., Ko, W. C., Tang, H. J., and Hsueh, P. R. (2020) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int. J. Antimicrob. Agents 55 (3), 105924.

(2) Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., Bi, Y., Ma, X., Zhan, F., Wang, L., Hu, T., Zhou, H., Hu, Z., Zhou, W., Zhao, L., Chen, J., Meng, Y., Wang, J., Lin, Y., Yuan, J., Xie, Z., Ma, J., Liu, W. J., Wang, D., Xu, W., Holmes, E. C., Gao, G. F., Wu, G., Chen, W., Shi, W., and Tan, W. (2020) Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395 (10224), 565–574.

(3) Zhou, P., Yang, X. L., Wang, X. G., Hu, B., Zhang, L., Zhang, W., Si, H. R., Zhu, Y., Li, B., Huang, C. L., Chen, H. D., Chen, J., Luo, Y., Guo, H., Jiang, R. D., Liu, M. Q., Chen, Y., Shen, X. R., Wang, X., Zheng, X. S., Zhao, K., Chen, Q. J., Deng, F., Liu, L. L., Yan, B., Zhan, F. X., Wang, Y. Y., Xiao, G. F., and Shi, Z. L. (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579 (7798), 270–273.

(4) Vinayagam, S., and Satu, K. (2020) SARS-CoV-2 and coagulation disorders in different organs. Life Sci. 260, 118431.

(5) Ortega-Paz, L., Capodanno, D., Montalescot, G., and Angiolillo, D. J. (2020) COVID-19 Associated Thrombosis and Coagulopathy: Review of the Pathophysiology and Implications for Antithrombotic Management. J. Am. Heart Assoc, e019650.

(6) Lu, H. (2020) Drug treatment options for the 2019-new coronavirus (2019-nCoV). BioSci. Trends 14 (1), 69–71.

(7) Sheahan, T. P., Sims, A. C., Leist, S. R., Schafer, A., Won, J., Brown, A. J., Montgomery, S. A., Hogg, A., Babusis, D., Clarke, M. O., Spannh, J. E., Bauer, L., Sellers, S., Porter, D., Feng, J. Y., Cihlar, T., Jordan, R., Denison, M. R., and Baric, R. S. (2020) Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat. Commun. 11 (1), 222.

(8) Pillayair, T., Meenakshisundaram, S., and Manickam, M. (2020) Recent discovery and development of inhibitors targeting coronaviruses. Drug Discovery Today 25 (4), 668–688.

(9) Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., and Xiao, G. (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30 (3), 269–271.

(10) Liu, J., Cao, R., Xu, M., Wang, X., Zhang, H., Hu, L., Li, Y., Hu, Z., Zhong, W., and Wang, M. (2020) Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 6, 16.

(11) te Velthuis, A. J., van den Worm, S. H., Sims, A. C., Baric, R. S., Snijder, E. J., and van Hemert, M. J. (2010) Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. PLoS Pathog. 6 (11), e1001176.

(12) Derwond, R., and Scholz, M. (2020) Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today’s battle against COVID-19? Med. Hypotheses 142, 109815.

(13) Touret, F., Gilles, M., Barral, K., Nougarede, A., van Helden, J., Decroly, E., de Lamballerie, X., and Coutard, B. (2020) In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication. Sci. Rep. 10 (1), 13093.

(14) Choy, K. T., Wong, A. Y., Kaewpreedee, P., Sia, S. F., Chen, D., Hui, K. P. Y., Chu, D. K. W., Chan, M. C. W., Cheung, P. P., Huang, X., Peiris, M., and Yen, H. L. (2020) Remdesivir, lopinavir, emetine, and homokahortonine inhibit SARS-CoV-2 replication in vitro. Antivir Res. 178, 104786.

(15) Eastman, R. T., Roth, J. S., Brimacombe, K. R., Simeonov, A., Shen, M., Patnaik, S., and Hall, M. D. (2020) Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19. ACS Cent. Sci. 6 (5), 672–683.

(16) Li, G., and De Clercq, E. (2020) Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat. Rev. Drug Discovery 19 (3), 149–150.

(17) Li, W., Moore, M. J., Vasilevna, N., Sui, J., Wong, S. K., Betne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Gerngroth, T. C., Choe, H., and Farzan, M. (2003) Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426 (6965), 450–454.

(18) Glowacki, I., Bertram, S., Muller, M. A., Allen, P., Soilleux, E., Pfefferle, S., Steffen, I., Tsegaye, T. S., He, Y., Gniirs, K., Niemeyer, W., and Hofmann, A. (2020) Remdesivir inhibits SARS-CoV-2 replication in vitro: A new potential therapeutic for COVID-19. ACS Cent. Sci. 6 (5), 672–683.
D. Schneider, H., Drosten, C., and Pohlmann, S. (2011) Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. *J. Virol. 85* (9), 4122–34.

(19) Shirato, K., Kawase, M., and Matsuyma, S. (2013) Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2. *J. Virol. 87* (23), 12552–61.

(20) Yamamoto, M., Matsuyma, S., Li, X., Takeda, M., Kawaguchi, Y., Inoue, J. I., and Matsuda, Z. (2016) Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay. *Antimicrob. Agents Chemother.* 60 (11), 6532–6539.

(21) Hoffmann, M., Kleine-Weber, H., Schroeder, S., Kruger, N., Herrler, T., Erichsen, S., Schierrgen, T. S., Herrler, G., Wu, N. H., Nitsche, A., Muller, M. A., Drosten, C., and Pohlmann, S. (2020) SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* 181 (2), 271–280.

(22) Bestle, D., Heindl, M. R., Limburg, H., Van Lam van, T., Pilgram, O., Moulton, H., Stein, D. A., Hardes, K., Eickmann, M., Dolnik, O., Rohde, C., Klenk, H. D., Garten, W., Steinmetzer, T., and Bottcher-Friebertshauer, E. TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. *Life Sci. Alliance* 2020, 3 (9). DOI: 10.26508/lsa.202000786

(23) Hoffmann, M., Hofmann-Winkler, H., Smith, J. C., Kruger, N., Sorensen, L. K., Sogaard, O. S., Hasselstrom, J. B., Winkler, M., Hempel, T., Raich, L., Olsson, S., Yamazoe, T., Yamatsuta, K., Mizuno, H., Ludwig, S., Noe, F., Shtelter, J. M., Kjolby, M., and Pohlmann, S. (2020) Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity. *bioRxiv*, DOI: 10.1101.2020.08.08.237651.

(24) Naik, B., Gupta, N., Ojha, R., Singh, S., Prapajati, V. K., and Prusty, D. (2020) High throughput virtual screening reveals SARS-CoV-2 multi-target binding natural compounds to lead instant therapy for COVID-19 treatment. *Int. J. Biol. Macromol.* 160, 1–17.

(25) Shrimp, J. H., Kales, S. C., Simeonov, A., Shen, M., and Hall, M. D. (2020) An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19. *bioRxiv*, DOI: 10.1101/2020.06.23.167544.

(26) Gorskhov, K., Chen, C. Z., Bostwick, R., Rasmussen, L., Xu, M., Pradhan, M., Tran, B. N., Zhu, W., Shamim, K., Huang, W., Hu, X., Shen, M., Klumpp-Thomas, C., Itkin, Z., Shino, P., Simeonov, A., Michael, S., Hall, M. D., Lo, D. C., and Zheng, W. (2020) The SARS-CoV-2 cytopathic effect is blocked with agonist modulators. *bioRxiv*, DOI: 10.1101.2020.05.16.091520.

(27) Roy, A., Kucukural, A., and Zhang, Y. (2010) I-TASSER: a unified platform for automated protein structure and function prediction. *Nat. Protoc.* 5 (4), 725–38.

(28) Herter, S., Piper, D. E., Aaron, W., Gabriele, T., Cutler, G., Cao, P., Bhatt, A. S., Choe, Y., Craik, C. S., Walker, N., Meininger, D., Howy, T., and Austin, R. J. (2005) Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers. *Biochem. J.* 390, 125–36.

(29) Guertin, K. R., Gardner, C. J., Klein, S. I., Zulli, A. L., Czekaj, M., Gong, Y., Spada, A. P., Cheney, D. L., Maingnan, S., Guilloteau, J. P., Brown, K. D., Colussi, D. J., Chu, V., Heran, C. L., Morgan, S. R., Bentley, R. G., Dunwiddie, C. T., Leadley, R. J., and Pauls, H. W. (2002) Optimization of the beta-aminoester class of factor Xa inhibitors. Part 2: Identification of FXV673 as a potent and selective Factor Xa inhibitor. *J. Med. Chem.* 45, 4051–24.

(30) Case, D. A., Ben-Shalom, I. Y., Brozell, S. R., Cerutti, D. S., Hu, X., Zhang, Y. Q., Lee, O. W., Liu, L., Tang, M. L., Kai, X., Boxer, M. B., Hall, M. D., and Shen, M. (2019) Discovery of novel inhibitors of human galactokinase by virtual screening. *J. Comput.-Aided Mol. Des.* 33 (4), 405–417.

(31) Hawkins, P. C., Skillman, A. G., and Nicholls, A. (2007) Comparison of shape-matching and docking as virtual screening tools. *J. Med. Chem.* 50 (1), 74–82.

(32) Chen, C. Z., Xu, M., Pradhan, M., Gorskhov, K., Petersen, J., Straus, M. R., Zhu, W., Shino, P., Guo, H., Shen, M., Klumpp-Thomas, C., Michael, S. G., Zimmerberg, J., Zheng, W., and Whittaker, G. R. (2020) Identifying SARS-CoV-2 entry inhibitors through drug repurposing screens of SARS-S and MERS-S pseudotyped particles. *bioRxiv*, DOI: 10.1101.2020.07.19.79888.

(33) Millet, J. K., and Whittaker, G. R. Murine Leukemia Virus (MLV)-based Coronavirus Spike-pseudotyped Particle Production and Infection. *Bio Protoc* 2016, 6 (23). DOI: 10.21769/BioProtoc.2035

(34) Rensi, S., Altman, R. B., Liu, T., Lo, Y. C., McInnes, G. Derry, A., and Keys, A. (2020) Homology Modeling of TMPRSS2 Yields Candidate Drugs That May Inhibit Entry of SARS-CoV-2 into Human Cells. *ChemRxiv*, DOI: 10.26434/chemrxiv.12009582.v1.

(35) Hedstrom, L. (2002) Serine protease mechanism and specificity. *Chem. Rev.* 102 (12), 4501–24.

(36) Hempel, T., Raich, L., Olsson, S., Azouz, N., Klingler, A., Rothenberg, M., and Noe, F. (2020) Molecular mechanism of SARS-CoV-2 cell entry inhibition via TMPRSS2 by Camostat and Nafamostat mesylate. *bioRxiv*, DOI: 10.1101.2020.07.21.214098.

(37) Sun, Y. J., Velez, G., Parsons, D., Bassuk, A. G., and Mahajan, V. (2021) TMPRSS2 structure-phylogeny repositioning Avoralstat for SARS-1 CoV-2 prophylaxis in mice. *bioRxiv*, DOI: 10.1101/2021.04.425289.

(38) Zhu, W., Xu, M., Chen, C. Z., Guo, H., Shen, M., Hu, X., Shinn, P., Klumpp-Thomas, C., Michael, S. G., and Zheng, W. (2020) Identification of SARS-CoV-2 XCL Protease Inhibitors by a Quantitative High-throughput Screening. *bioRxiv*, DOI: 10.1101/2020.07.17.207019.

(39) Guertin, K. R., and Choi, Y. M. (2007) The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development. *Curr. Med. Chem.* 14 (23), 2471–81.
(47) Liao, Y., Bottcher, H., Harting, J., Greiner, H., van Amsterdam, C., Cremers, T., Sundell, S., Marz, J., Rautenberg, W., and Wikstrom, H. (2000) New selective and potent 5-HT(1B/1D) antagonists: chemistry and pharmacological evaluation of N-piperazinylphenyl biphenylcarboxamides and biphenylsulfonamides. J. Med. Chem. 43 (3), 517–25.

(48) Sturzebecher, J., Vieweg, H., Steinmetzer, T., Schweinitz, A., Stubbs, M. T., Renatus, M., and Wikstrom, P. (1999) 3-Amidinophenylalanine-based inhibitors of urokinase. Bioorg. Med. Chem. Lett. 9 (21), 3147–52.

(49) Gimeno, A., Mestres-Truyol, J., Ojeda-Montes, M. J., Macip, G., Saldivar-Espinoza, B., Cereto-Massague, A., Pujadas, G., and Garcia-Vallve, S. (2020) Prediction of Novel Inhibitors of the Main Protease (M-pro) of SARS-CoV-2 through Consensus Docking and Drug Reposition. Int. J. Mol. Sci. 21 (11), 3793 DOI: 10.3390/ijms21113793.

(50) Sun, W., Zhang, X., Cummings, M. D., Albarazanji, K., Wu, J., Wang, M., Alexander, R., Zhu, B., Zhang, Y., Leonard, J., Lanter, J., and Lenhard, J. (2020) Targeting enteropeptidase with reversible covalent inhibitors to achieve metabolic benefits. J. Pharmacol. Exp. Ther. 375, 510.

(51) Sanderson, P. E. (1999) Small, noncovalent serine protease inhibitors. Med. Res. Rev. 19 (2), 179–97.